Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) – Investment analysts at Jefferies Group decreased their FY2017 earnings per share estimates for shares of Verona Pharma PLC American Depositary Share in a research report issued on Tuesday. Jefferies Group analyst P. Welford now forecasts that the company will post earnings of ($2.91) per share for the year, down from their prior estimate of ($2.64). Jefferies Group also issued estimates for Verona Pharma PLC American Depositary Share’s Q4 2017 earnings at ($0.67) EPS, FY2018 earnings at ($2.72) EPS, FY2019 earnings at ($3.78) EPS and FY2021 earnings at ($2.32) EPS.

TRADEMARK VIOLATION NOTICE: This story was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/11/11/verona-pharma-plc-american-depositary-share-expected-to-post-fy2017-earnings-of-2-91-per-share-vrna.html.

Other analysts have also issued research reports about the company. Zacks Investment Research upgraded Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, July 25th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $24.20.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) opened at $12.48 on Friday. Verona Pharma PLC American Depositary Share has a twelve month low of $11.03 and a twelve month high of $17.50.

A number of large investors have recently added to or reduced their stakes in VRNA. FIL Ltd purchased a new stake in Verona Pharma PLC American Depositary Share during the 2nd quarter valued at $873,000. Tekla Capital Management LLC bought a new position in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $3,211,000. Finally, Vivo Capital LLC bought a new position in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $8,208,000. Institutional investors own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Earnings History and Estimates for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.